Developer docs
API playgroundTry for free, no card

Search company profiles

Salutas Pharma GmbH

Full company profile

uuid00596tx

Namestring
Salutas Pharma GmbH
Websiteurl
salutas.de
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Salutas Pharma GmbH is a Germany-based pharmaceutical manufacturer operating two production facilities in Barleben and Osterweddingen, with a total headcount of 206 employees. The company is referenced within the Sandoz Deutschland corporate footprint, indicating it functions as a manufacturing subsidiary within Sandoz, one of the world's largest generics pharmaceutical companies. The two sites are classified as manufacturing/production facilities, consistent with Salutas Pharma's role as a production node rather than a standalone commercial entity with its own go-to-market. The company's corporate domicile is Germany, and its entire disclosed operational footprint is domestic.

No specific products, formulations, or technology stack are disclosed in the available source data. As a Sandoz-affiliated generics manufacturer, Salutas Pharma's implied product surface is solid oral dosage forms and other generic pharmaceutical formats typical of large-scale European generics manufacturing, but this is inferred from the parent company context rather than explicitly stated. There is no disclosed AI capability, no proprietary technology platform, no patents, and no certifications documented in the source. The company does not disclose an app, API, or software product.

The business model is implicit but not formalized in the source data. Salutas Pharma is a private subsidiary (per the source's classification, though ownership name is not declared) engaged in pharmaceutical manufacturing. Pricing models, revenue mechanics, and customer segments are not disclosed. Given the Sandoz parent relationship, the most plausible model is internal capacity contribution to Sandoz's European generics supply, with commercial revenue captured at the parent-group level rather than at the entity level. The company has no disclosed partnerships, no M&A history, no funding rounds, and no management team data in the provided input.

Short descriptiontext

Salutas Pharma GmbH is a German pharmaceutical manufacturer operating two production sites in Barleben and Osterweddingen within the Sandoz group, employing 206 staff in generics manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBarleben, Germany
HQ citystring
Barleben
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, pharmaceutical manufacturing, oral solid dosage, active pharmaceutical ingredients, generic medicine production
Industry4 codes
1Generic Finished Dosage Form (FDF) Manufacturing
CodeHLAIABAHPrimaryYes
2Small-Molecule Generics (Branded/Unbranded)
CodeHLAIABAAPrimaryNo
3Generic APIs & Intermediates (Active Ingredients)
CodeHLAIABAGPrimaryNo
4Oral Solid Dose (OSD) Generics
CodeHLAIABADPrimaryNo
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
Social media profiles1 record
Cost components4 values
Personnel, Operations, Supply Chain, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Salutas Pharma GmbH operates as a German pharmaceutical manufacturer, with production sites in Barleben and Osterweddingen producing generic medicines. The company manufactures and supplies generic pharmaceutical products as part of the Sandoz manufacturing network, focusing on cost-efficient oral solid dosage generics for European and global markets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product information available for Salutas Pharma GmbH in the provided source data. The source only references a Sandoz Deutschland page regarding manufacturing locations in Barleben und Osterweddingen, Germany.

Product and service1 record
1Generic pharmaceutical products (manufactured at Barleben and Osterweddingen sites)
CategoryGeneric Pharmaceuticals
Description

Generic medicines (including oral solid dosage forms) manufactured at Salutas Pharma's Barleben and Osterweddingen German production sites and supplied through the Sandoz generics network to wholesalers, pharmacy chains, and health systems globally.

No data
Peers10 records
TypeEmerging player
Description

Alvotech is a biosimilars-focused manufacturer expanding its European manufacturing presence. While focused on biosimilars rather than small-molecule generics, it is emerging as a potential competitor for Sandoz-related manufacturing capacity and represents adjacent category pressure on Salutas.

TypeBroad incumbent
Description

Apotex is a large global generic pharmaceutical manufacturer with European market presence. Comparable to Salutas as a generics broad incumbent active in small-molecule finished dosage forms, though primarily Canadian-headquartered.

TypeBroad incumbent
Description

Viatris is a global generics and specialty pharmaceutical powerhouse with a broad European generics portfolio. Comparable to Salutas as a broad incumbent in the same product category, though at significantly greater scale and geographic diversification.

TypeDirect peer
Description

Ratiopharm is a leading German generics brand (now part of Teva) with established manufacturing and a similar value proposition in the small-molecule generics market. Highly comparable to Salutas in product category and German market positioning.

TypeDirect peer
Description

Hexal is Sandoz's German sister subsidiary and one of the largest generics manufacturers in Germany. Directly comparable as a German-based generics operation within the same Sandoz group, operating in the same product categories and regulatory environment as Salutas.

TypeDirect peer
Description

Stada is a major German-headquartered generic pharmaceutical manufacturer with significant production in Germany. Directly comparable to Salutas in geography, therapeutic focus on generics, and European manufacturing footprint.

7Merckle GmbH (Heumann / Haemato Pharma)
TypeRegional player
Description

Merckle is a German-based pharmaceutical group with manufacturing and generics activities. It is comparable to Salutas as a regional German pharmaceutical manufacturer with similar regulatory and market dynamics.

TypeBroad incumbent
Description

Teva is the world's largest generic pharmaceutical manufacturer with significant German operations through ratiopharm. While substantially larger and more diversified, it competes directly with Salutas in the broader European generics market.

TypeBroad incumbent
Description

Hikma is a multinational generic pharmaceutical manufacturer with a European footprint. It competes with Salutas in European generic markets and shares the same business model of producing small-molecule generic finished dosage forms.

TypeDirect peer
Description

Aurobindo's German operations supply generic finished dosage forms across European markets, giving it a directly comparable product portfolio and customer base to Salutas within the European generic pharmaceutical supply chain.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Salutas Pharma GmbH

Generic Pharmaceuticalssalutas.de

Salutas Pharma GmbH is a German pharmaceutical manufacturer operating two production sites in Barleben and Osterweddingen within the Sandoz group, employing 206 staff in generics manufacturing.

What Salutas Pharma GmbH does

Salutas Pharma GmbH is a Germany-based pharmaceutical manufacturer operating two production facilities in Barleben and Osterweddingen, with a total headcount of 206 employees. The company is referenced within the Sandoz Deutschland corporate footprint, indicating it functions as a manufacturing subsidiary within Sandoz, one of the world's largest generics pharmaceutical companies. The two sites are classified as manufacturing/production facilities, consistent with Salutas Pharma's role as a production node rather than a standalone commercial entity with its own go-to-market. The company's corporate domicile is Germany, and its entire disclosed operational footprint is domestic.

No specific products, formulations, or technology stack are disclosed in the available source data. As a Sandoz-affiliated generics manufacturer, Salutas Pharma's implied product surface is solid oral dosage forms and other generic pharmaceutical formats typical of large-scale European generics manufacturing, but this is inferred from the parent company context rather than explicitly stated. There is no disclosed AI capability, no proprietary technology platform, no patents, and no certifications documented in the source. The company does not disclose an app, API, or software product.

The business model is implicit but not formalized in the source data. Salutas Pharma is a private subsidiary (per the source's classification, though ownership name is not declared) engaged in pharmaceutical manufacturing. Pricing models, revenue mechanics, and customer segments are not disclosed. Given the Sandoz parent relationship, the most plausible model is internal capacity contribution to Sandoz's European generics supply, with commercial revenue captured at the parent-group level rather than at the entity level. The company has no disclosed partnerships, no M&A history, no funding rounds, and no management team data in the provided input.

Salutas Pharma GmbH firmographics

Firmographics
Name
Salutas Pharma GmbH
Website
https://salutas.de
Company type
Private
Operating status
Operating
Headcount range
101–250 employees
Short description
Salutas Pharma GmbH is a German pharmaceutical manufacturer operating two production sites in Barleben and Osterweddingen within the Sandoz group, employing 206 staff in generics manufacturing.
Ownership category
akta.pro rank

Salutas Pharma GmbH industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
akta.pro secondary industries
Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Oral Solid Dose (OSD) Generics (HLAIABAD)

Keywords

  • Generic pharmaceuticals
  • Pharmaceutical manufacturing
  • Oral solid dosage
  • Active pharmaceutical ingredients
  • Generic medicine production

Where Salutas Pharma GmbH is headquartered

Location

Headquarters

HQ city
Barleben
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Salutas Pharma GmbH business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D

Salutas Pharma GmbH product offering

Product offering

Core offering

Salutas Pharma GmbH operates as a German pharmaceutical manufacturer, with production sites in Barleben and Osterweddingen producing generic medicines. The company manufactures and supplies generic pharmaceutical products as part of the Sandoz manufacturing network, focusing on cost-efficient oral solid dosage generics for European and global markets.

Product overview

No product information available for Salutas Pharma GmbH in the provided source data. The source only references a Sandoz Deutschland page regarding manufacturing locations in Barleben und Osterweddingen, Germany.

Differentiator

Problem solved

Functional benefit

Products and services

  • Generic pharmaceutical products (manufactured at Barleben and Osterweddingen sites) Generic medicines (including oral solid dosage forms) manufactured at Salutas Pharma's Barleben and Osterweddingen German production sites and supplied through the Sandoz generics network to wholesalers, pharmacy chains, and health systems globally.

Companies that use Salutas Pharma GmbH

Customer profile

Ideal customer profiles1 record

Salutas Pharma GmbH technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Salutas Pharma GmbH competitors and assessment

Company assessment

Emerging players

  • Alvotech: Alvotech is a biosimilars-focused manufacturer expanding its European manufacturing presence. While focused on biosimilars rather than small-molecule generics, it is emerging as a potential competitor for Sandoz-related manufacturing capacity and represents adjacent category pressure on Salutas.

Broad incumbents

  • Apotex Inc. Apotex is a large global generic pharmaceutical manufacturer with European market presence. Comparable to Salutas as a generics broad incumbent active in small-molecule finished dosage forms, though primarily Canadian-headquartered.
  • Viatris (Mylan): Viatris is a global generics and specialty pharmaceutical powerhouse with a broad European generics portfolio. Comparable to Salutas as a broad incumbent in the same product category, though at significantly greater scale and geographic diversification.
  • Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with significant German operations through ratiopharm. While substantially larger and more diversified, it competes directly with Salutas in the broader European generics market.
  • Hikma Pharmaceuticals: Hikma is a multinational generic pharmaceutical manufacturer with a European footprint. It competes with Salutas in European generic markets and shares the same business model of producing small-molecule generic finished dosage forms.

Direct peers

  • Ratiopharm GmbH: Ratiopharm is a leading German generics brand (now part of Teva) with established manufacturing and a similar value proposition in the small-molecule generics market. Highly comparable to Salutas in product category and German market positioning.
  • Hexal AG: Hexal is Sandoz's German sister subsidiary and one of the largest generics manufacturers in Germany. Directly comparable as a German-based generics operation within the same Sandoz group, operating in the same product categories and regulatory environment as Salutas.
  • Stada Arzneimittel AG: Stada is a major German-headquartered generic pharmaceutical manufacturer with significant production in Germany. Directly comparable to Salutas in geography, therapeutic focus on generics, and European manufacturing footprint.
  • Aurobindo Pharma Deutschland: Aurobindo's German operations supply generic finished dosage forms across European markets, giving it a directly comparable product portfolio and customer base to Salutas within the European generic pharmaceutical supply chain.

Regional players

  • Merckle GmbH (Heumann / Haemato Pharma): Merckle is a German-based pharmaceutical group with manufacturing and generics activities. It is comparable to Salutas as a regional German pharmaceutical manufacturer with similar regulatory and market dynamics.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Salutas Pharma GmbH social profiles

Digital presence

Salutas Pharma GmbH financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Salutas Pharma GmbH leadership team

Management profile

Number of profiles

Salutas Pharma GmbH funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Salutas Pharma GmbH M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Salutas Pharma GmbH

What does Salutas Pharma GmbH do?

Salutas Pharma GmbH operates as a German pharmaceutical manufacturer, with production sites in Barleben and Osterweddingen producing generic medicines. The company manufactures and supplies generic pharmaceutical products as part of the Sandoz manufacturing network, focusing on cost-efficient oral solid dosage generics for European and global markets.

Is Salutas Pharma GmbH a public or private company?

Salutas Pharma GmbH is a private company. It is classified as corporate owned and is currently operating.

When was Salutas Pharma GmbH founded?

Salutas Pharma GmbH was founded in -1. It employs 101 to 250 people.

Where is Salutas Pharma GmbH based?

Salutas Pharma GmbH is headquartered in Barleben, Germany, in the Europe region.

Who are Salutas Pharma GmbH's main competitors?

Alvotech is listed as an emerging player. Broad incumbents are Apotex Inc., Viatris (Mylan), Teva Pharmaceutical Industries and Hikma Pharmaceuticals. Direct peers are Ratiopharm GmbH, Hexal AG, Stada Arzneimittel AG and Aurobindo Pharma Deutschland. Merckle GmbH (Heumann / Haemato Pharma) is listed as a regional player.

Does Salutas Pharma GmbH have an API?

No public API is recorded for Salutas Pharma GmbH.

What industry is Salutas Pharma GmbH in?

Salutas Pharma GmbH's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAA, Small-Molecule Generics (Branded/Unbranded). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireInternationaler Hotspot für PharmatechnologieSaxony-Anhalt in Germany has established itself as a leading pharmaceutical and biotech hub, with companies like Bayer, Salutas, IDT Biologika, WACKER, Merz, Mibe, and Oncotec producing approximately eight billion tablets annually in the region. The three regional partners MFAG, WFS, and IMG jointly promote the area under the 'airea' brand, showcasing the region's complete pharmaceutical value chain from R&D to production and logistics. Notable investments include Icon Genetics announcing a 50 million euro production facility and WACKER committing over 100 million euros to expand its mRNA competency center at the Weinberg Campus, which will more than triple production capacity and double employee numbers.PR NewswireInternational hub for pharmaceutical techSaxony-Anhalt in central Germany has established itself as a leading pharmaceutical and biotech hub, with major manufacturers including Bayer Bitterfeld, Salutas, IDT Biologika, Wacker, Merz, Mibe, and Oncotec collectively producing billions of tablets and other medical products annually. The region features a comprehensive pharmaceutical value chain from R&D to logistics, anchored by the CEIV Pharma-certified Leipzig/Halle Airport and the Weinberg Campus Technology Park in Halle (Saale). Wacker is investing over 100 million euros to build an mRNA production center at Weinberg Campus, which will more than triple production capacity and more than double the workforce, while Icon Genetics GmbH (a subsidiary of Japan's Denka) is constructing a separate 50-million-euro production facility at the same technology park.